News from janssen pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jun 25, 2015, 08:57 ET

INVEGA TRINZA™, First and Only Four-Times-A-Year Treatment for Schizophrenia, Now Commercially Available

The first schizophrenia treatment to be taken just four times a year – with dosing measured in seasons, not days – is now available in...

May 28, 2015, 08:30 ET

New Clinical Research Program Initiated for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer

 Janssen Pharmaceuticals, Inc. (Janssen) and its development partner, Bayer HealthCare, today announced the initiation of CALLISTO, a new...

May 19, 2015, 16:05 ET
Janssen Logo.

Janssen Enters into a Worldwide Collaboration with Achillion Pharmaceuticals, Inc. to Combat Hepatitis C Virus

Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has entered...

May 19, 2015, 08:17 ET

U.S. FDA Approves INVEGA TRINZA™, First and Only Four-Times-A-Year Treatment for Schizophrenia

 There's a new treatment option for schizophrenia – INVEGA TRINZA™ (three-month paliperidone palmitate), the first and only...

May 18, 2015, 08:30 ET

New Real-World Data Show Adults with Type 2 Diabetes, Including Those Taking Multiple Diabetes Medications, Achieve Blood Glucose Treatment Goals After Using INVOKANA® (canagliflozin)

 Janssen Pharmaceuticals, Inc. (Janssen) today announced results from three real-world analyses, which found significant improvements in blood...

May 15, 2015, 08:00 ET

Real-World Data Presented at American Geriatrics Society Meeting Show Consistent Safety of XARELTO® in Elderly Patients

New data from an ongoing post-marketing study evaluating the safety of once-daily XARELTO® (rivaroxaban) in patients with non-valvular atrial...

May 14, 2015, 14:46 ET

New Data on XARELTO® Versus Vitamin K Antagonists in Atrial Fibrillation Patients Undergoing Catheter Ablation Presented at Heart Rhythm 2015

 Janssen Pharmaceuticals, Inc. and its development partner, Bayer HealthCare, today announced results from the VENTURE-AF trial. The study...

May 11, 2015, 17:47 ET

U.S. FDA Issues Complete Response Letter to sNDA Seeking to Expand the Label for INVEGA SUSTENNA®

Janssen Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response...

May 11, 2015, 08:00 ET

Johnson & Johnson Expands IP Policy to Create Broad Access in 128 Countries for Development of New and Optimized HIV Medicine Formulations for Children Living with HIV

 Johnson & Johnson today announced that its Janssen Pharmaceutical Companies have furthered their commitment to improve the health of...

Apr 28, 2015, 08:00 ET
Why U.S. Hispanics Require a Tailored Approach to Type 2 Diabetes Care

Janssen Launches U.S. Hispanic Community Initiative to Help Improve Type 2 Diabetes Care

 Janssen Pharmaceuticals, Inc., the manufacturer of INVOKANA® (canagliflozin) for the treatment of type 2 diabetes, today announced the...

Apr 28, 2015, 08:00 ET

Janssen lanza iniciativa en la comunidad hispana en EE. UU. para ayudar a mejorar el cuidado de la diabetes tipo 2

Janssen Pharmaceuticals, Inc., fabricante de INVOKANA® (canagliflozina) para el tratamiento de la diabetes tipo 2, anunció hoy el...

Apr 15, 2015, 08:30 ET

Study Published in The Journal of Clinical Psychiatry Shows INVEGA SUSTENNA® Effective Six Months Longer Than Common Oral Antipsychotics in Treatment of Schizophrenia

 A study published in The Journal of Clinical Psychiatry yesterday shows that long-acting INVEGA SUSTENNA® (paliperidone palmitate) was...

Apr 02, 2015, 16:07 ET

Janssen Pharmaceuticals, Inc. Completes Divestiture of U.S. License Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended-release tablets and NUCYNTA® (tapentadol) Oral Solution to Depomed, Inc.

 Janssen Pharmaceuticals, Inc. (JPI) today announced it has completed the divestiture of its U.S. license rights to NUCYNTA® (tapentadol),...

Mar 19, 2015, 04:00 ET

Janssen Acquires XO1 Limited

Janssen Pharmaceuticals, Inc. (Janssen), one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired...

Jan 15, 2015, 16:05 ET

Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest U.S. License Rights to NUCYNTA® (tapentadol), NUCYNTA® ER (tapentadol) extended-release tablets and NUCYNTA® (tapentadol) Oral Solution

Janssen Pharmaceuticals, Inc. (JPI) today announced it has entered into a definitive agreement with Depomed, Inc. to divest its U.S. license rights...

Dec 05, 2014, 08:00 ET

Janssen Teams Up with the American Diabetes Association to Take On Type 2 Diabetes

Janssen Pharmaceuticals, Inc. (Janssen) today announced a collaboration with the American Diabetes Association (Association) to launch Teaming Up...

Nov 13, 2014, 08:45 ET

U.S. FDA Approves Supplemental New Drug Applications for Once-Monthly Long-Acting Therapy INVEGA® SUSTENNA® (paliperidone palmitate) for the Treatment of Schizoaffective Disorder

Janssen Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Applications...

Oct 20, 2014, 16:05 ET

Janssen Pharmaceuticals and Diabetes Hands Foundation Encourage People with Type 2 Diabetes to Get Moving for National Diabetes Month

Janssen Pharmaceuticals, Inc. has teamed up with the Diabetes Hands Foundation to raise awareness about the importance of incorporating...

Sep 24, 2014, 16:30 ET

Study Observed Association between JANSSEN® CONNECT® Injection Centers and Increased Adherence to Healthcare Provider-Ordered Janssen Long-Acting Treatment for People with Schizophrenia

 Janssen Pharmaceuticals, Inc. announced the results of a first-of-its-kind study, The Impact of JANSSEN® CONNECT® Injection Centers...

Aug 25, 2014, 08:25 ET

Janssen Affiliate Cilag GmbH International Acquires Covagen AG

Cilag GmbH International, an affiliate of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced today that it has acquired...